NCT00915135已完成2 期
A Double-Blind, Dose-Response, Cross-Over Study of TAK-375 With Chronic Insomnia (Phase II Study) -- Polysomnographic Evaluation
Takeda0 个研究点目标入组 66 人开始时间: 2002年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 66
- 主要终点
- Mean Latency to Persistent Sleep
研究概览
简要总结
The purpose of this study is to determine the dose response of Ramelteon, once daily (QD), in Japanese subjects with Chronic Insomnia
详细描述
Complaints of sleep disorder are increasing with today's aging society and changing lifestyle. Sleep disorders not only impact one's activities of daily living, but also impede one's social life, leading to reduced productivity and sometimes accidents through carelessness.
Ramelteon is a melatonin-1 receptor agonist under global development by Takeda Chemical Industries, Ltd., Osaka, Japan, for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has primary chronic insomnia for at least 3 months.
- •Has a mean latency of greater than or equal to 20 minutes on 2 consecutive polysomnography screening nights with no night less than 15 minutes, and has a mean of at least 60 minutes of wake time across 2 nights with no night less than 45 minutes.
- •Has a habitual bedtime between 8:30 PM and 12:00 AM.
- •Has a body mass index that is not less than 17, but less than
- •Females of childbearing potential who are sexually active must agree to use a medically accepted means of contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
排除标准
- •Has a history of psychiatric disorder (including depression and anxiety), seizures, drug addiction, sleep apnea, nocturnal myoclonus and/or mental retardation as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
- •Has a history of alcohol abuse within the previous 2 years.
- •Has a hepatic disease, and a significant neurological, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological or metabolic disease.
- •Has a known hypersensitivity to ramelteon or related compounds, including melatonin.
- •Has a positive hepatitis panel including hepatitis A, hepatitis B or hepatitis C.
- •Has any clinically abnormal findings as determined by a medical history, physical examination, electrocardiogram or clinical laboratory tests by the investigator or sub investigator.
- •Has experienced 3 hours or more of jet lag within 7 days preceding the polysomnography screening.
- •Has an apnea-hypopnea index (per hour of sleep) greater than or equal to 10 as seen on the first night of polysomnography screening.
- •Has periodic limb movement with arousal index (per hour o sleep) greater than or equal to 10 as seen on the first night of polysomnography screening.
- •Has participated in an excessive weight loss program that may have given influence on the evaluation of this study, or altered the participant's exercise routine within 30 days prior to double-blind study medication administration.
- •Has had a clinically significant illness within 30 days prior to double-blind study medication administration.
- •Has had sleep schedule changes required by employment (e.g., shift worker) within 3 months prior to double-blind study medication administration.
- •The investigator or sub investigator judges the study subject inappropriate for participation because it is considered difficult to complete the study, or participating in the study will not be in the best interest of the subject.
研究组 & 干预措施
Ramelteon QD and Placebo QD (25 possible combinations total)
Experimental
干预措施: Ramelteon and Placebo (25 possible combinations total) (Drug)
结局指标
主要结局
Mean Latency to Persistent Sleep
时间窗: Mean of Nights 1 and 2.
次要结局
- Mean Total Sleep Time(Mean of Nights 1 and 2.)
- Sleep Efficiency(Mean of Nights 1 and 2)
- Awake Time after Persistent Sleep(Mean of Nights 1 and 2.)
- Percent of Total Sleep Time in NREM sleep Stage 1(Mean of Nights 1 and 2.)
- Percent of Total Sleep Time in NREM sleep Stage 2(Mean of Nights 1 and 2.)
- Percent of Total Sleep Time in NREM sleep Stage 3/4(Mean of Nights 1 and 2.)
- Percent of Total Sleep Time in REM sleep Stage(Mean of Nights 1 and 2.)
- Latency to REM sleep stage(Mean of Nights 1 and 2.)
- Subjective Sleep Latency(Mean of Nights 1 and 2.)
- Subjective Total Sleep Time(Mean of Nights 1 and 2.)
- Subjective Sleep Quality(Mean of Nights 1 and 2.)
研究者
相似试验
已完成
3 期
Safety and Efficacy of Ramelteon in Adults With Chronic InsomniaBalanceNCT00237497Takeda275
已完成
2 期
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's DiseaseChronic InsomniaNCT00325728Takeda74
已完成
4 期
Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.Chronic InsomniaNCT00414102Takeda552
终止
3 期
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I DisorderAcute Depressive EpisodeNCT01467700Takeda490
已完成
3 期
Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.Chronic InsomniaNCT00247390Takeda451